These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 6090179

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment.
    Yoburn BC, Goodman RR, Cohen AH, Pasternak GW, Inturrisi CE.
    Life Sci; 1985 Jun 17; 36(24):2325-32. PubMed ID: 2989632
    [Abstract] [Full Text] [Related]

  • 3. Naltrexone-induced opiate receptor supersensitivity.
    Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR.
    Brain Res; 1982 Aug 12; 245(2):285-92. PubMed ID: 6289965
    [Abstract] [Full Text] [Related]

  • 4. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
    Hahn EF, Nishimura S, Goodman RR, Pasternak GW.
    J Pharmacol Exp Ther; 1985 Dec 12; 235(3):839-45. PubMed ID: 2416909
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
    Ward SJ, Takemori AE.
    J Pharmacol Exp Ther; 1983 Mar 12; 224(3):525-30. PubMed ID: 6131119
    [Abstract] [Full Text] [Related]

  • 7. Effects of beta-funaltrexamine on radiolabeled opioid binding.
    Recht LD, Pasternak GW.
    Eur J Pharmacol; 1987 Aug 11; 140(2):209-14. PubMed ID: 2822439
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oxymorphone-naltrexonazine, a mixed opiate agonist-antagonist.
    Galetta S, Hahn EF, Nishimura S, Pasternak GW.
    Life Sci; 1987 Aug 10; 41(6):783-7. PubMed ID: 2441221
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamic supersensitivity and opioid receptor upregulation in the mouse.
    Yoburn BC, Nunes FA, Adler B, Pasternak GW, Inturrisi CE.
    J Pharmacol Exp Ther; 1986 Oct 10; 239(1):132-5. PubMed ID: 3020228
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.
    Rothman RB, Long JB, Bykov V, Jacobson AE, Rice KC, Holaday JW.
    J Pharmacol Exp Ther; 1988 Nov 10; 247(2):405-16. PubMed ID: 2846819
    [Abstract] [Full Text] [Related]

  • 15. Behavioral effects of opioid peptides selective for mu or delta receptors. I. Morphine-like discriminative stimulus effects.
    Locke KW, Holtzman SG.
    J Pharmacol Exp Ther; 1986 Sep 10; 238(3):990-6. PubMed ID: 3018230
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chronic morphine upregulates a mu-opiate binding site labeled by [3H]cycloFOXY: a novel opiate antagonist suitable for positron emission tomography.
    Rothman RB, McLean S, Bykov V, Lessor RA, Jacobson AE, Rice KC, Holaday JW.
    Eur J Pharmacol; 1987 Oct 06; 142(1):73-81. PubMed ID: 2826178
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists.
    Takemori AE, Portoghese PS.
    Eur J Pharmacol; 1984 Sep 03; 104(1-2):101-4. PubMed ID: 6094203
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.